# Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo

> **NCT03097861** · PHASE3 · COMPLETED · sponsor: **Sucampo Pharma Americas, LLC** · enrollment: 552 (actual)

## Conditions studied

- Chronic Idiopathic Constipation

## Interventions

- **DRUG:** Lubiprostone
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03097861
- **Lead sponsor:** Sucampo Pharma Americas, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-13
- **Primary completion:** 2017-08-17
- **Final completion:** 2017-08-17
- **Target enrollment:** 552 (ACTUAL)
- **Last updated:** 2020-01-14

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03097861

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03097861, "Evaluation of the Bioequivalence of Sprinkle and Capsule Formulations of Lubiprostone, as Compared to Placebo". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT03097861. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*